The Obesity Society's 30th Annual Meeting
The meeting brings exciting insights on drugs and mobile health.
By Nina Ran, Hannah Deming, and Kira Maker, diaTribe
The 30th Annual Meeting of The Obesity Society (TOS) brought researchers, members of industry, and clinicians to San Antonio for five days of learning. The conference featured over 100 oral presentations, more than 850 posters, and more than 60 booths in the exhibit hall. Below are some of our biggest takeaways from the meeting.
The Potential of Anti-Obesity Drugs
The optimism for anti-obesity drugs was more tangible than ever on the heels of the recent FDA approvals of Vivus' Qsymia and Arena/Eisai's Belviq. Dr. Ken Fujioka (Scripps Health, San Diego) believed the approvals would "change the landscape," while Dr. Preston Klassen (Orexigen, La Jolla, CA) noted that is currently a "fantastic time for the obesity space." Though little new data were presented on medications, some physicians even expressed interest in both Qsymia and Belviq to treat diabetes, especially on top of anti-glycemic drugs like metformin or GLP-1 agonists.
Vivus stole the show, as it launched Qsymia just two days before the meeting began. There were plenty of purple and white advertisements for Qsymia throughout the conference hall. By contrast, Eisai's presence was understated, as Belviq must still pass through the Drug Enforcement Agency's classification process (launch of Belviq is expected in early 2013). Vivus demonstrated their online free patient support program, Q and Me, which has since been launched and is available at http://www.qandmesupport.com. The program is designed to support people taking Qsymia (but available to those not on the drug too) with tools and resources for weight loss (e.g., food and activity logs, a weight tracker, a recipe search, and food analyzer). We are glad that Vivus has made the lifestyle-focused Q and Me program available to anyone — while an obesity medication like Qsymia will certainly help people lose weight, it's certainly not a magic bullet or cure-all, and healthy living through diet and exercise will be key for keeping weight off long term.
What's Next for Mobile Health?
The Obesity Society 2012 dipped its toe into mobile health (mHealth) for weight loss but also reminded us that there is a long way to go before effective, evidence-based mHealth solutions will be available for patients. Of course, there's no shortage of options with over 1,000 weight-related applications available for Apple and Android phones! However, speakers reminded us that while many solutions seem promising, it is important to scientifically evaluate mHealth strategies to ensure that people can have access to efficacious, validated products.
We were particularly impressed by a presentation on Zamzee — the product is a two-part mHealth solution that includes a kid-friendly monitor that tracks activity and a motivational, incentive-based online website. Over a six-month trial, the 200+ children using Zamzee averaged 44 more minutes per week of moderate/vigorous physical activity compared to the group not using the device! This translated to a 4.5-fold increase in the number of days that the kids reached the Centers for Disease Control recommended level of 60 minutes of moderate or vigorous physical activity. Encouragingly, the increased activity in the Zamzee group was sustained over time and was slightly stronger in the second half of the study. We have been testing Zamzee internally since mid-summer here at diaTribe — overall, although we've had a few problems associated with losing or breaking Zamzees, the early reviews have been very high, and at $29 per Zamzee (membership to the website is free with purchase of the device), this could certainly be a solution for large groups of children. The device is currently for purchase at www.zamzee.com.
Combating Obesity Through Soda Bans
The topic of sugary drinks received considerable attention at The Obesity Society, particularly during a debate on whether decreasing their consumption would decrease obesity. Both presenters referenced the rather two-side information on the subject and no clear winner was established. The conference also included discussion on whether a tax on sugary drinks (similar to the current taxes on tobacco) could increase health awareness and provide cost savings. Dr. Steven Gortmaker (Harvard School of Public Health, Boston) estimated that a one cent per ounce tax on these drinks could reduce national healthcare costs by $1,700 per dollar spent, raise $12.7 billion each year in taxes, and lead to health benefits beyond those directly related to weight loss. Dr. Frank Chaloupka came to a similar conclusion: a penny per ounce tax on sugar sweetened beverages would generate approximately $15 billion in additional revenue per year. Now wouldn't that be something to put toward obesity educations, subsidizing healthier foods, and exercise!
This article is published on dLife thanks to diaTribe (www.diaTribe.us), an independent, advertising-free e-newsletter for everyone eager to learn about the latest advances in diabetes management. diaTribe is your inside track on diabetes research and products — sign up here for your complimentary lifetime subscription!
NOTE: This information is not intended to be a replacement or substitute for consultation with a qualified medical professional or for professional advice related to diabetes or another medical condition. Please contact your physician or medical professional with any questions and concerns about your medical condition.
Dried Cranberry Sauce Rosemary and Sherry Pork Chops Lemon Pepper Red Snapper 15-Minute Beef Barbecue Peach Crisp Peachy Berry Cobbler Strawberry-Topped Cheesecake Handmade Cinnamon Rolls Individual Bread Pudding Snacks Chicken Quesadillas
A few years ago, I wrote about a friend whose struggles with Disability left him without insulin for weeks at a time. Today, I ask those of you who follow the tradition to light a blue candle for "Tiny", who passed from this world yesterday morning. From what I know, this young man (he was no older than 37, and may not have even reached the age of 30) had early onset type 2...